^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    navtemadlin (KRT-232)

    i
    Company:
    Amgen, Kartos Therap
    Drug class:
    MDM2 inhibitor
    Related drugs:
    Apply
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TP53 • CD4
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)
    Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (ALLIANCE-ABTC-1604) (NCT03107780)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/09/2018
    Primary completion :
    03/21/2019
    Completion :
    02/07/2026
    TP53 • MGMT
    |
    TP53 wild-type
    |
    navtemadlin (KRT-232)
    Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (NRG-DT001) (NCT03217266)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    06/20/2018
    Primary completion :
    08/27/2023
    Completion :
    02/28/2025
    TP53 • MDM2 • MDM4 • CD4
    |
    navtemadlin (KRT-232)
    Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (NCT03031730)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/14/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TP53 • CD4
    |
    TP53 mutation
    |
    lenalidomide • carfilzomib • dexamethasone • navtemadlin (KRT-232) • Hemady (dexamethasone tablets)
    TL-895 and KRT-232 Study in Acute Myeloid Leukemia (NCT04669067)
    Phase 1b/2
    Telios Pharma, Inc.
    Active, not recruiting
    Last update posted :
    02/17/2023
    Initiation :
    03/31/2021
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    TP53 • FLT3
    |
    FLT3-ITD mutation • FLT3 mutation • TP53 wild-type
    |
    navtemadlin (KRT-232) • M7583
    KRT-232 and TKI Study in Chronic Myeloid Leukemia (KRT-232-117) (NCT04835584)
    Phase 1b/2
    Kartos Therapeutics, Inc.
    Recruiting
    Last update posted :
    03/21/2022
    Initiation :
    05/07/2021
    Primary completion :
    12/31/2024
    Completion :
    06/30/2026
    ABL1 • BCR
    |
    TP53 wild-type
    |
    dasatinib • Tasigna (nilotinib) • navtemadlin (KRT-232)